Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 20 Best Performing Stocks in 2025.
On December 11, 2025, TheFly reported that Citizens boosted its price goal for Terns Pharmaceuticals, Inc. to $57 from $35. The firm retained an Outperform rating, noting interim Phase 1 CARDINAL ASH data confirming a best-in-class profile for TERN-701. The firm identified strong activity after asciminib and ponatinib, which it considers favorable for second-line use, and a high deep molecular response rate that supports first-line potential.
Terns Pharmaceuticals, Inc. released third-quarter 2025 results and corporate updates, pointing out that an ASH 2025 abstract featured unprecedented Phase 1 CML efficacy data and a possible best-in-disease profile for TERN-701. An expanded and updated CARDINAL dataset is anticipated to be included in an upcoming ASH oral presentation.
Separately, the firm reported $295.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from $358.2 million as of December 31, 2024. The company stated that current funds are anticipated to cover planned operating costs until 2028.
Nonetheless, the stock is down by 3.07% as of January 6, 2026.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical business.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
